How to treat fungal infections in ICU patients

BMC Infectious Diseases

George Dimopoulos¹  Theodora Christodoulopoulou¹  Dimitrios K Matthaiou¹ 

[1]Department of Critical Care, University Hospital ATTIKON, Medical School, University of Athens, 1 Rimini str, Haidari-Athens 12462, Greece

关键词: Fungal infections;    Critical Care;    ICU;    Aspergillus;    Candida;   

Others  :  1179036
DOI  :  10.1186/s12879-015-0934-8

 received in 2015-03-27, accepted in 2015-04-21,  发布年份 2015

【 摘 要 】

Fungal infections represent a major burden in the critical care setting with increasing morbidity and mortality. Candidiasis is the leading cause of such infections, with C. albicans being the most common causative agent, followed by Aspergillosis and Mucormycosis. The diagnosis of such infections is cumbersome requiring increased clinical vigilance and extensive laboratory testing, including radiology, cultures, biopsies and other indirect methods. However, it is not uncommon for definitive evidence to be unavailable. Risk and host factors indicating the probability of infections may greatly help in the diagnostic approach. Timely and adequate intervention is important for their successful treatment. The available therapeutic armamentarium, although not very extensive, is effective with low resistance rates for the newer antifungal agents. However, timely and prudent use is necessary to maximize favorable outcomes.

【 授权许可】

   
2015 Matthaiou et al.; licensee BioMed Central.

【 参考文献 】

• [1]Blot S, Dimopoulos G, Rello J, Vogelaers D: Is Candida really a threat in the ICU? Curr Opin Crit Care 2008, 14(5):600-4.
• [2]Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20(1):133-63.
• [3]Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M: Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008, 47(2):e17-24.
• [4]Tragiannidis A, Tsoulas C, Kerl K, Groll AH: Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opin Pharmacother 2013, 14(11):1515-28.
• [5]Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi De Carvalho F, et al.: Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012, 38(12):1930-45.
• [6]Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004, 39(3):309-17.
• [7]Alangaden GJ: Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 2011, 25(1):201-25.
• [8]Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C: The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010, 14(6):R222.
• [9]van de Veerdonk FL, Kullberg BJ, Netea MG: Pathogenesis of invasive candidiasis. Curr Opin Crit Care 2010, 16(5):453-9.
• [10]Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al.: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42(4):1519-27.
• [11]Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al.: Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 48(12):1695-703.
• [12]Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al.: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48(4):1366-77.
• [13]Dimopoulos G, Karabinis A, Samonis G, Falagas ME: Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007, 26(6):377-84.
• [14]Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME: Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008, 106(2):523-9.
• [15]Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R: Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220(6):751-8.
• [16]Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, et al.: Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37(5):1624-33.
• [17]Calderaro A, Martinelli M, Motta F, Larini S, Arcangeletti MC, Medici MC, et al.: Comparison of peptide nucleic acid fluorescence in situ hybridization assays with culture-based matrix-assisted laser desorption/ionization-time of flight mass spectrometry for the identification of bacteria and yeasts from blood cultures and cerebrospinal fluid cultures. Clin Microbiol Infect 2014, 20(8):O468-75.
• [18]Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M: Value of (1–3)-beta-d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect 2011, 17(10):1549-53.
• [19]Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al.: Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012, 54(9):1240-8.
• [20]Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al.: ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl 7):19-37.
• [21]Playford EG, Lipman J, Sorrell TC: Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010, 16(5):470-4.
• [22]Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al.: Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 2012, 18(7):680-7.
• [23]Simon J, Sun HY, Leong HN, Barez MY, Huang PY, Talwar D, et al.: Echinocandins in invasive candidiasis. Mycoses 2013, 56(6):601-9.
• [24]Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al.: MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014, 58(9):1219-26.
• [25]Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 48(5):503-35.
• [26]Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al.: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000, 79(4):250-60.
• [27]Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF, Campbell JW, et al.: Invasive aspergillosis due to Neosartorya udagawae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 49(1):102-11.
• [28]Blot S, Koulenti D, Dimopoulos G: Invasive Pulmonary Aspergillosis in Critically Ill Patients. In Annual Update in Intensive Care and Emergency Medicine 2013. edn. Edited by Vincent J-L. Springer, Berlin Heidelberg; 2013:63-75.
• [29]Denning DW: Invasive aspergillosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998, 26(4):781-803.
• [30]Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al.: Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43(Suppl 1):S49-58.
• [31]Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100(13):4358-66.
• [32]Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002, 34(7):909-17.
• [33]Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R: The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2009, 13(1):24-36.
• [34]Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001, 32(3):358-66.
• [35]Diamond RD, Krzesicki R, Epstein B, Jao W: Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978, 91(2):313-28.
• [36]Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E: Invasive aspergillosis in the intensive care unit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007, 45(2):205-16.
• [37]Luong ML, Chaparro C, Stephenson A, Rotstein C, Singer LG, Waters V, et al.: Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014, 97(3):351-7.
• [38]Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP 3rd: Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001, 119(1):169-75.
• [39]Dimopoulos G, Tsangaris I, Poulakou G, Panayiotides J, Tsaknis G, Orfanos S, et al.: Post-operative Aspergillus mediastinitis in a man who was immunocompetent: a case report. J Med Case Reports 2010, 4:312.
• [40]Pasqualotto AC, Denning DW: Post-operative aspergillosis. Clin Microbiol Infect 2006, 12(11):1060-76.
• [41]Meyer RD, Young LS, Armstrong D, Yu B: Aspergillosis complicating neoplastic disease. Am J Med 1973, 54(1):6-15.
• [42]Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al.: Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 2011, 17(12):1882-9.
• [43]Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M: Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 2013, 13:29.
• [44]Barberan J, Sanz F, Hernandez JL, Merlos S, Malmierca E, Garcia-Perez FJ, et al.: Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. J Infect 2012, 65(5):447-52.
• [45]Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK: A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009, 37(4):313-9.
• [46]Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect 2012, 18(4):403-8.
• [47]Aliyali M, Hedayati MT, Habibi MR, Khodavaisy S: Clinical risk factors and bronchoscopic features of invasive aspergillosis in intensive care unit patients. J Prev Med Hyg 2013, 54(2):80-2.
• [48]Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, et al.: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005, 9(3):R191-9.
• [49]Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F: Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 2004, 59(5):251-7.
• [50]Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al.: Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 2012, 38(11):1761-8.
• [51]Baddley JW: Clinical risk factors for invasive aspergillosis. Med Mycol 2011, 49(Suppl 1):S7-12.
• [52]De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008, 46(12):1813-21.
• [53]Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO: Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care 2006, 21(4):322-7.
• [54]Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al.: A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012, 186(1):56-64.
• [55]Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al.: Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006, 10(1):R31.
• [56]Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al.: Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006, 43(5):577-84.
• [57]Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al.: The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001, 33(11):1824-33.
• [58]Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al.: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002, 20(7):1898-906.
• [59]Agca H, Ener B, Yilmaz E, Ursavas A, Kazak E, Ozkocaman V, et al.: Comparative evaluation of galactomannan optical density indices and culture results in bronchoscopic specimens obtained from neutropenic and non-neutropenic patients. Mycoses 2014, 57(3):169-75.
• [60]Hizel K, Kokturk N, Kalkanci A, Ozturk C, Kustimur S, Tufan M: Polymerase chain reaction in the diagnosis of invasive aspergillosis. Mycoses 2004, 47(7):338-42.
• [61]Hsu JL, Ruoss SJ, Bower ND, Lin M, Holodniy M, Stevens DA: Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol 2011, 37(4):277-312.
• [62]Li Y, Gao L, Ding Y, Xu Y, Zhou M, Huang W, et al.: Establishment and application of real-time quantitative PCR for diagnosing invasive aspergillosis via the blood in hematological patients: targeting a specific sequence of Aspergillus 28S-ITS2. BMC Infect Dis 2013, 13:255.
• [63]Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al.: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 48(8):1042-51.
• [64]Panackal AA, Parisini E, Proschan M: Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2014, 28:80-94.
• [65]Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al.: An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011, 183(1):96-128.
• [66]Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008, 46(3):327-60.
• [67]Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002, 35(4):359-66.
• [68]Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98(2):292-9.
• [69]Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003, 51(2):313-6.
• [70]Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005, 41(5):634-53.
• [71]Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G: Invasive fungal infections in the ICU: how to approach, how to treat. Molecules (Basel, Switzerland) 2014, 19(1):1085-119.
• [72]Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS: Recent advances in the management of mucormycosis: from bench to bedside. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 48(12):1743-51.
• [73]Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117(9):2649-57.
• [74]Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al.: The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012, 67(3):715-22.
• [75]Tacke D, Koehler P, Markiefka B, Cornely OA: Our 2014 approach to mucormycosis. Mycoses 2014, 57(9):519-24.